Exclusion of single-hit TP53mut t-MDS from the TP53 mutated MDS have huge impact on management such as consideration for allogeneic stem cell transplantation [34], and exclusion from clinical trials targeted toward TP53mut MDS. This evidence concerns the gene TP53 and myelodysplastic syndrome.